



Function of *hsa_circ_0006646* as a competing endogenous RNA to promote progression in gastric cancer by regulating the *miR-665-HMGB1* axis

Jing Qin^{1,2^}, Shuman Zhen^{1^}, Jiali Wang^{1^}, Wei Lv^{1^}, Yan Zhao^{1^}, Yuqing Duan^{1^}, Tianxu Liu^{1^}, Lei Feng^{2^}, Guiying Wang^{3^}, Lihua Liu^{1,4^}

¹Department of Tumor Immunotherapy, Fourth Hospital of Hebei Medical University, Shijiazhuang, China; ²Department of General Surgery, Third Hospital of Shijiazhuang, Shijiazhuang, China; ³Department of General Surgery, Second Hospital of Hebei Medical University, Shijiazhuang, China; ⁴International Cooperation Laboratory of Stem Cell Research, Hebei Medical University, Shijiazhuang, China

Contributions: (I) Conception and design: J Qin, G Wang, L Liu; (II) Administrative support: S Zhen, J Wang; (III) Provision of study materials or patients: J Qin, W Lv, Y Zhao; (IV) Collection and assembly of data: Y Duan, T Liu, L Feng; (V) Data analysis and interpretation: J Qin, J Wang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Guiying Wang, PhD. Department of General Surgery, Second Hospital of Hebei Medical University, 215 Heping West Road, Xinhua District, Shijiazhuang 050004, China. Email: wangguiyingtgzy@163.com; Lihua Liu, PhD. Department of Tumor Immunotherapy, Fourth Hospital of Hebei Medical University, 169 Tianshan Street, Yuhua District, Shijiazhuang 050035, China; International Cooperation Laboratory of Stem Cell Research, Hebei Medical University, Shijiazhuang, China. Email: cdlihua@aliyun.com.

Background: Mounting evidences indicate that circular RNAs (circRNAs) are a novel class of non-coding RNAs and play vital roles in the tumorigenesis and aggressiveness including gastric cancer (GC). Nevertheless, the precise functions and underlying mechanisms of circRNAs in GC remain largely unknown.

Methods: The Gene Expression Omnibus (GEO) data set GSE163416 was analyzed to screen the key circRNAs in GC. *hsa_circ_0006646* was chosen for further study. GC tissues and matched adjacent normal gastric mucosal epithelial tissues were obtained from the Fourth Hospital of Hebei Medical University. The expressions of *hsa_circ_0006646* was detected using quantitative real-time polymerase chain reaction (qRT-PCR). *hsa_circ_0006646* was knocked down to identify its effects on GC cells. Bioinformatics algorithms were analyzed to predict the microRNA (miRNAs) potentially sponged by *hsa_circ_0006646* and its target genes. Fluorescence in situ hybridization (FISH) was conducted to determine the subcellular location of *hsa_circ_0006646* and the predicted miRNA. Then, qRT-PCR, luciferase reporter assay, radioimmunoprecipitation assay, Western blotting, and miRNA rescue experiments were used to confirm the *hsa_circ_0006646*-related regulatory axis in GC. Cell Counting Kit-8 (CCK-8), colony formation, wound healing, and Transwell experiments were performed to determine the effect of the *hsa_circ_0006646*-related regulatory axis on GC cells' malignant behaviors *in vitro*. The xenograft tumor mouse model was established to evaluate the effect of *hsa_circ_0006646* *in vivo*.

Results: *hsa_circ_0006646* exhibited a high expression in GC tissues as compared to corresponding adjacent normal gastric mucosal epithelial tissues and its high expression was positively correlated with TNM stage, lymph node invasion and poor prognosis ($P < 0.05$). Knockdown of *hsa_circ_0006646* suppressed the proliferation, colony formation, migration, and invasion in GC cells (all $P < 0.05$). *hsa_circ_0006646* upregulated high mobility group box 1 (*HMGB1*) by sponging *miR-665* in GC cells ($P < 0.05$). The *hsa_circ_0006646*-*miR-665*-*HMGB1* axis promoted malignant behaviors and epithelial-mesenchymal transition (EMT) in GC cells by activating the Wnt/ β -catenin pathway ($P < 0.05$). The existence of *hsa_circ_0006646*-

[^] ORCID: Jing Qin, 0000-0001-7130-5299; Shuman Zhen, 0000-0002-2095-1546; Jiali Wang, 0000-0002-8052-2575; Wei Lv, 0000-0002-4119-8864; Yan Zhao, 0000-0003-2285-2709; Yuqing Duan, 0000-0001-7249-2815; Tianxu Liu, 0000-0001-7820-6170; Lei Feng, 0000-0001-5680-8904; Guiying Wang, 0000-0001-9601-8210; Lihua Liu, 0000-0001-5078-0656.

miR-665-HMGB1 axis was confirmed in GC specimens ($P < 0.05$). Consequently, down-regulated *hsa_circ_0006646* inhibited the progression and EMT of GC cells *in vivo* ($P < 0.05$).

Conclusions: For the first time, we demonstrated that *hsa_circ_0006646-miR-665-HMGB1* axis exerted its tumor-promoting effects in GC, which suggested that *hsa_circ_0006646* could be potentially targeted for GC treatment.

Keywords: Gastric cancer (GC); *hsa_circ_0006646*; *miR-665*; high mobility group box 1 (*HMGB1*); epithelial-mesenchymal transition (EMT)

Submitted Mar 20, 2023. Accepted for publication May 05, 2023. Published online May 15, 2023.

doi: 10.21037/jgo-23-240

View this article at: <https://dx.doi.org/10.21037/jgo-23-240>

Introduction

Gastric cancer (GC) is the fifth most common cancer and the third major cause of cancer-related death worldwide, especially in developing countries (1). Although many advances have been achieved in terms of the diagnosis and treatment of GC, the overall 5-year survival rate is still less than 30%, as most patients with GC are found to be in the advanced stage when they are first diagnosed (2). Moreover, the functions and regulatory mechanisms of precise molecules involved in GC are still little known, which has made progress in the clinical treatment of GC considerably difficult. Thus, elucidating the underlying exact mechanisms in tumorigenesis and progression of GC is essential to providing evidence for discovering novel biomarkers and prognostic indicators for early diagnosis and treatment.

Circular RNAs (circRNAs) constitute a class of noncoding RNAs characterized by a covalently closed single-stranded

loop and a canonical splicing junction site (3). Emerging studies have revealed that circRNAs are involved in multiple biological processes, such as inflammation, renal fibrosis, and tumorigenesis (4,5). CircRNAs exhibit multiple functions in cellular processes including cell cycle regulation, proliferation, migration, invasion, apoptosis, and autophagy (6). Since circRNAs are stable, conserved, and abundant in cancers, some specific circRNAs have been deemed to be of great value for treating cancer patients (3). circRNAs regulate biological behavior through multiple mechanisms, with circRNA's acting as a competing endogenous RNA (ceRNA) to sponge microRNA (miRNA) being the most common and well-studied mechanism in cancer (7). In brief, circRNAs competitively sponge miRNAs to abolish their inhibition on target messenger RNAs (mRNAs), and thereby upregulate the expression of corresponding genes (8). For instance, *circUBR5* acts as a ceRNA for *miR-1179* to up-regulate *UBR5* and to promote malignancy of triple-negative breast cancer (9). Additionally, *circFOXO1* acts as a ceRNA to upregulate *SMAD2* and promote the progression of nasopharyngeal carcinoma (10). Moreover, *circIFT80* functions as a ceRNA for *miR-142*, *miR-568*, and *miR-634* and Promotes the Progression of Colorectal Cancer by Targeting β -Catenin (11). However, the function and exact mechanisms of circRNAs involved in tumorigenesis and progression of GC are largely unknown and need further exploration.

In the present study, we identified *hsa_circ_0006646*, which originates from exon 3 and exon 4 of the *PTK2* gene, as a tumor-promoting circRNA in GC. *hsa_circ_0006646* was upregulated in GC tissues and cell lines. High expression of *hsa_circ_0006646* was positively correlated with TNM stage, lymph node invasion and poor prognosis. In addition, *hsa_circ_0006646* silencing suppressed GC cell proliferation, migration, invasion and epithelial-

Highlight box

Key findings

- It has been definitely confirmed that *hsa_circ_0006646* promotes the progression of GC by regulating the *miR-665-HMGB1* axis.

What is known and what is new?

- *miR-665* is a tumor-suppressive miRNA in GC and *HMGB1* has been reported to be involved in the progression of GC.
- *hsa_circ_0006646* promotes the progression of GC by upregulating *HMGB1* and activating the Wnt/ β -catenin signaling pathway through sponging *miR-665*.

What is the implication, and what should change now?

- The study provides a novel insight into the mechanism underlying the circRNA-induced progression of GC and could lead to the development of a potential biomarker and therapeutic target for treating GC.

mesenchymal transition (EMT) *in vitro*. *hsa_circ_0006646* knockdown inhibited GC growth *in vivo*. Moreover, we identified that *hsa_circ_0006646* promoted the progression of GC by sponging *miR-665* to relieve its downregulation of high mobility group box 1 (*HMGB1*) expression. Furthermore, we demonstrated that the *hsa_circ_0006646-miR-665-HMGB1* axis promoted the progression and EMT of GC cells by activating the Wnt/ β -catenin signaling pathway. To our knowledge, this is the first report of the role *hsa_circ_0006646-miR-665-HMGB1* axis in GC and it provides potential therapeutic targets for GC. We present this article in accordance with the ARRIVE reporting checklist (available at <https://jgo.amegroups.com/article/view/10.21037/jgo-23-240/rc>).

Methods

Bioinformatic analysis

The Gene Expression Omnibus (GEO) dataset GSE163416 was downloaded from the database (<http://www.ncbi.nlm.nih.gov/geo/>) to screen the circRNAs involved in GC. The high throughput sequencing data were analyzed by using the “limma” package in R software (The R Foundation for Statistical Computing). The cutoff value of fold-change was set as 2. The circRNAs with $P < 0.05$ were regarded as the differentially expressed circRNAs between GC and normal gastric tissues.

Prediction of circRNA-targeted miRNAs

To further demonstrate the potential mechanism of *hsa_circ_0006646* in GC, the interacting miRNAs of *hsa_circ_0006646* were predicted with circBank (<http://www.circbank.cn/>) and circInteractome (<https://circinteractome.nia.nih.gov/>).

Predicting the target genes of miRNAs

The databases of FunRich, miRWalk, TargetScan, and miRDB (12–15) were used to predict the target mRNAs of *miR-665*. By overlapping the results of analysis, we found the common predicted target genes exhibiting possibly regulated by *miR-665*.

Clinical specimens

To establish a validation cohort, GC tissues and matched

adjacent normal gastric mucosal epithelial tissues were obtained from 35 pairs of patients with GC who underwent gastroscopy biopsy in the Fourth Hospital of Hebei Medical University (Shijiazhuang, China). None of the patients enrolled in this study had received preoperative treatment, including radiotherapy, chemotherapy, or immunotherapy. Each specimen was divided into 2 pieces and handled as follows: 1 piece was fixed in 10% formaldehyde for making paraffin-embedded blocks, and the other piece was immediately frozen in liquid nitrogen for extracting RNA. All patients provided informed consent. This study was conducted in accordance with the principles of the Declaration of Helsinki (as revised in 2013). Approval was granted by the ethics committee of Fourth Hospital of Hebei Medical University (No. 2019-082).

Cell culture

The normal human gastric epithelial mucosa cell line (GES-1) and GC cell line (AGS) were purchased from BNCC Biotechnology (Henan, China). Human GC cell lines (HGC27, MKN45, and MKN74) were gifted by the Research Center of Fourth Hospital of Hebei Medical University. GES-1 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM; Gibco, USA) medium supplemented with 10% fetal bovine serum (FBS; Gibco, Thermo Fisher Scientific, Waltham, MA, USA), while the other GC cell lines were cultured in RPMI-1640 (Gibco, USA) medium supplemented with 10% FBS. Cells were incubated at 37 °C in a humidified atmosphere of 5% CO₂.

RNA extraction and quantitative real-time polymerase reaction

The total RNAs were extracted by using TRIzol Reagent (Solarbio, Beijing, China), and genomic DNA (gDNA) were isolated with Fast Pure DNA Isolation Kit (Vazyme Biotech CO., Nanjing, China). For detecting circRNAs and mRNAs, RNA was reversely transcribed into cDNA using a Revert Aid First Strand cDNA Synthesis kit (Thermo Fisher Scientific). For detecting miRNAs, cDNA was synthesized with the Prime Script RT Reagent Lit (Takara Bio, Kusatsu, Japan). RNA expression was quantified by quantitative real-time polymerase chain reaction (qRT-PCR) with a SYBR Green PCR Kit (Takara Bio). Relative expression was determined using the 2^{- $\Delta\Delta C_T$} method (16). *GAPDH* was used as internal control to normalize the expression of circRNAs and mRNAs. *U6* was used as internal control to

Table 1 Primers used in this study for qRT-PCR

Name	Primer	Sequence (5'-3')
<i>hsa_circ_0006646</i>	Forward primer	ATTCCGCCTCAGTCACCT
	Reverse primer	CTAGGTATCTGTCATATTTCCA
<i>LinearPTK2</i>	Forward primer	TGGGCGGAAAGAAATCCTGC
	Reverse primer	GGCTTGACACCCTCGTTGTA
<i>GAPDH</i>	Forward primer	AGAAGGCTGGGGCTCATTTG
	Reverse primer	GCAGGAGGCATTGCTGATGAT
<i>miR-665</i>	Forward primer	ACCAGGAGGCTGAGGC
	Reverse primer	GAACATGTCTGCGTATCTC
<i>miR-139-3p</i>	Forward primer	GCCCTGTTGGAGTGTCGTAT
	Reverse primer	GTATCCAGTGCGTGTCGTGG
<i>miR-1322</i>	Forward primer	GATGATGCTGCTGATGCTG
	Reverse primer	GAUGAUGCUGCUGAUGCUG
<i>U6</i>	Forward primer	CAAGGATGACACGCAA
	Reverse primer	TCAACTGGTGTCGTGG
<i>HMGB1</i>	Forward primer	TGCAGATGACAAGCAG CCTT
	Reverse primer	GCTGCATCAGGCTTTCCTTT

qRT-PCR, quantitative real-time polymerase chain reaction; *U6* was used as an internal control to normalize *miR-665*, *miR-139-3p* and *miR-1322* expression, and *GAPDH* was used as a control to normalize the expressions of *hsa_circ_0006646* and *HMGB1*; *HMGB1*, high mobility group box 1.

Table 2 Oligonucleotides used in this study

Definition	Sequence (5'-3')
si- <i>hsa_circ_0006646</i> #1	CAGAGGAGTGGAATATG
si- <i>hsa_circ_0006646</i> #2	AGAGGAGTGGAATATGA
si- <i>hsa_circ_0006646</i> #3	GAGGAGTGGAATATGAC
si-NC	TTCTCCGAACGTGTACGT
sh- <i>hsa_circ_0006646</i> #1	CAGAGGAGTGGAATATGTCAAGAG CATATTTCCACTCCTCTGTTTTT
sh- <i>hsa_circ_0006646</i> #2	AGAGGAGTGGAATATGTCAAGAG TCATATTTCCACTCCTCTTTTTT
<i>miR-665</i> mimic	ACCAGGAGGCUGAGGCCCUU
<i>miR-665</i> inhibitor	ACCAGGAGGCUGAGGCCCUU

si, small interfering; sh, short hairpin; NC, negative control.

normalize the expression of miRNAs. Divergent primers were used to detect the back splice junction of circRNA, and convergent primers were used to detect linear mRNA. The primers are listed in *Table 1*.

Nucleic acid electrophoresis

The complementary DNA (cDNA) and genomic DNA (gDNA) PCR products were investigated using 2% agarose gel electrophoresis with Tris-acetate-EDTA running buffer. DNA was separated with electrophoresis at 90 V for 30 min. The DNA marker was Marker L (50-500 bp) (ZOMANBIO, Beijing, China). The bands were examined using ultraviolet irradiation.

RNase R treatment

Total RNA (2 µg) from AGS and HGC27 were incubated for 15 min at 37 °C with or without 3 U/mg of RNase R (Thermo Fisher Scientific, USA). Then, the resulting RNA was directly reverse-transcribed with divergent primer or convergent primer using a Revert Aid First Strand cDNA Synthesis kit (Thermo Fisher Scientific, USA) and detected by PCR assay and qRT-PCR assay.

Oligonucleotide transfection

AGS and HGC27 cells were seeded in 6-well plates and cultured to 60–70% confluence before transfection. Small interfering RNAs (siRNAs) targeting the back-splicing junction of *hsa_circ_0006646* (si-*hsa_circ_0006646*#1, si-*hsa_circ_0006646*#2 and si-*hsa_circ_0006646*#3) was designed and synthesized with GeneSeed (Guangzhou, China), while *miR-665* mimics, *miR-665* inhibitor, and negative control (si-NC) oligonucleotides were designed and synthesized by Biomics Biotech (Nantong, China). Lipofectamine 2000 (Invitrogen, USA) was used as transfection a medium according to the manufacturer's protocol. Oligonucleotide sequences are listed in *Table 2*.

Plasmid construction and stable transfection

The lentivirus-containing short hairpin RNA (shRNA) targeting *hsa_circ_0006646* (sh-*hsa_circ_0006646*#1,

sh-*bsa_circ_0006646*#2) was purchased from GeneSeed (Guangzhou, China). The sh-*bsa_circ_0006646*#1 and sh-*bsa_circ_0006646*#2 were transfected into AGS and HGC27 cells by using Lipofectamine 2000 (Invitrogen, USA). The transfection was performed according to the manufacturer's instructions. After being posttransfected for 48 h, the cells were selected with puromycin (2 µg/mL) for 2 weeks to construct stable cell lines. The transfection efficiency was verified with qRT-PCR. Stable transfection sequences are listed in Table 2.

Cell proliferation assay

The proliferation of AGS and HGC27 cells was evaluated by conducting Cell Counting Kit-8 (CCK-8) assay. Briefly, AGS and HGC27 cells were seeded into 96-well plates (1×10^3 cells/well) and cultured at 37 °C with 5% CO₂ for 0, 24, 48, and 72 h. At the indicated time points, 10 µL of CCK-8 reagent (Servicebio, Wuhan, China) was added to the culture medium. After incubation for 2 h, the absorbance of each well was measured at 450 nm using a microplate reader (BioTek Instruments, USA).

Colony formation assay

AGS and HGC27 cells were seeded into 6-well plates at a density of 800 cells/well and incubated at 37 °C in a humidified atmosphere of 5% CO₂ for 2 weeks. The number of clones larger than 50 cells was counted, and the colony formation rate was then calculated. Following this, the cells were washed with phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde for 20 min, and stained with a 0.1% crystal violet (Kaigen, Nanjing, China) solution for another 20 min. The colonies were photographed and counted.

Transwell assay

The Transwell chamber (Jet Biofil, Guangzhou, China) was covered with Matrigel mix (Jet Biofil) for invasion assays. AGS and HGC27 cells were seeded in upper chambers with 200 µL of serum-free medium. The bottom chamber was filled with medium and 10% FBS as the AGS and HGC27 cell chemoattractant. After 24 h, the upper chambers were fixed and then stained with 0.1% crystal violet (Kaigen) for 20 min. The cells were imaged and counted in 5 different fields.

Wound healing experiment

After the AGS and HGC27 cells were confluent to 80% in the 6-well plates, the AGS and HGC27 cells were scratched with a 200-µL micropipette tip in the center of the well to prepare a scratch wound. The cells were then incubated with serum-free medium. Representative images were captured at 0, 24, and 48 h after injury. The relative migration rate at 24 and 48 h was quantified and compared with 0 h.

Fluorescence in situ hybridization (FISH)

Digoxin-labeled *bsa_circ_0006646* and *miR-665* probes were designed and synthesized by Servicebio (Wuhan, China). They were used for analysis of the colocalization of *bsa_circ_0006646* and *miR-665* in AGS and HGC27 cells. The probe sequences were as follows: *bsa_circ_0006646*: 5'-DIG-GGTATCTGTCATATTTTCCACTCCTCTG-DIG-3'; and *miR-665*: 5'-DIG-AGGGGCCTCAGCCTCCTGGT-Dig-3'. Hybridization was performed overnight with *bsa_circ_0006646* and *miR-665* probes according to the manufacturer's instructions. The images were acquired on a fluorescence microscope (Nikon, Tokyo, Japan).

Western blotting

AGS and HGC27 cells were lysed in RIPA lysis buffer (Beyotime, Shanghai, China). The membranes were blocked with 5% skimmed milk and incubated overnight at 4 °C with the following primary antibodies. The primary antibodies were as follows: anti-*HMGB1* (1:1,000; Bioss, Beijing, China), anti-β-catenin (1:1,000; Bioss), anti-Wnt3a (1:1,000; Bioss), anti-c-Myc (1:1,000; Bioss), anti-E-cadherin (1:1,000; Servicebio), anti-N-cadherin (1:1,000; Servicebio), anti-Vimentin (1:1,000; Huabio, Hangzhou, China), anti-Snail (1:1,000; Huabio) and anti-*GAPDH* (1:4,000; GB11002, Servicebio) at 4 °C overnight. Then, the prepared membranes were incubated with secondary antibody (1:10,000, Bioss) for 2 h. Finally, the blots were visualized with an enhanced chemiluminescent reagent (Biosharp, Beijing, China).

Dual-luciferase reporter assay

The wild-type (WT) and mutated (MUT) *bsa_circ_0006646* and the 3' untranslated region (3'-UTR) of *HMGB1* mRNA

were synthesized and inserted into pEZX-MT06 luciferase plasmids (Hanbio, Shanghai, China). Subsequently, AGS and HGC27 cells were seeded at 5×10^4 cells/well in 24-well plates and allowed to settle overnight. After co-transfection with the constructed luciferase plasmids and *miR-665* mimics or negative control using Lipofectamine 2000 reagent (Invitrogen, USA) for 48 h, the relative luciferase activity was measured with the dual-luciferase reporter assay system (Promega, Madison, WI, USA).

RNA immunoprecipitation

RNA immunoprecipitation (RIP) assay was performed using a Magna RIP RNA-binding protein immunoprecipitation kit (BersinBio, Guangzhou, China) according to the manufacturer's protocol. In brief, AGS and HGC27 cells were harvested and lysed in complete RIP lysis buffer after transfected with *miR-665* mimics or negative control. Then, the cell extract was incubated with magnetic beads conjugated with anti-immunoglobulin G (IgG) or anti-Ago2 antibody (BersinBio, Guangzhou, China) for 6 h at 4 °C. The beads were washed and incubated with proteinase K to remove proteins. Finally, isolated RNA was extracted using TRIzol reagent (Solarbio, China), and the purified RNA was subjected to agarose gel electrophoresis and qRT-PCR analysis for detecting the enrichment of *hsa_circ_0006646* and *miR-665* in Ago2-immunoprecipitates.

Immunohistochemistry

The GC tissues were fixed with 10% formalin and embedded in paraffin before the sections were treated with the primary antibodies anti-*HMGB1* and anti- β -catenin. After being incubated at 4 °C overnight, the sections were washed twice and subsequently incubated with horseradish peroxidase (HRP) polymer-conjugated secondary antibody at room temperature. These samples were then stained with 3,3'-diaminobenzidine (DAB) solution and hematoxylin. Finally, the slides were observed through a microscope.

Mice xenograft model

All animal experiments were performed under a project license granted by the Ethics Committee of Fourth Hospital of Hebei Medical University (No. 2020-056) and in compliance with the Fourth Hospital of Hebei Medical University guidelines for the care and use of animals. A

protocol was prepared before the study without registration. To investigate the *hsa_circ_0006646* growth effect on GC cells *in vivo*, 4-week-old male BALB/C nude mice were acquired from Beijing Huafukang Biotechnology Co., LTD (Beijing, China), and 10 nude mice were randomly divided into 2 groups with 5 mice in each group. The AGS cells transfected with sh-*hsa_circ_0006646*#1 or sh-NC (negative control) were subcutaneously injected into right flank region of the legs (5×10^6 cells per mouse). Tumor size was measured from perpendicular axes and calculated using the following formula: volume = (length $\times$ width²)/2. Twenty-eight days later, mice were killed via spinal dislocation, and the xenograft tumors were dissected for tumor weight, Western blotting and Immunohistochemistry staining.

Statistical analysis

Statistical analyses were performed using SPSS 25.0 (IBM Corp., Armonk, NY, USA) and GraphPad Prism 9 (GraphPad Software, Inc., San Diego, CA, USA). All measurement data were presented as mean $\pm$ standard deviation and were analyzed using Student's *t*-test. The association between *hsa_circ_0006646* expression and clinicopathological features of GC was evaluated using the Chi-squared test. The survival analysis was analyzed using the Kaplan-Meier plot. Spearman rank correlation was used to analyze the association between *hsa_circ_0006646* and *miR-665* or between *HMGB1* and *miR-665* in GC specimens. All hypothesis tests were conducted by two-sided test, and the test level was 0.05. A value of $P < 0.05$ was considered statistically significant.

Results

hsa_circ_0006646 was found to be a circRNA exhibiting high expression in GC and positively correlated with poor prognosis

To verify the critical circRNAs that contribute to the tumorigenesis and progression of GC, we first screened the upregulated circRNAs in GC tissues by analyzing a public GEO data set GSE163416. As shown in Figure 1A, *hsa_circ_0006646* exhibited the most significant upregulation, among all candidate circRNAs. We then conducted qRT-PCR to validate the results from the GEO profile. As anticipated, the expression of *hsa_circ_0006646* was higher in GC tissues as compared to matched normal gastric mucosal epithelium tissues (Figure 1B). We then focused




Figure 1 *hsa_circ_0006646* was an upregulated circRNA in GC. (A) Heatmap according to the differentially expressed circRNAs between GC tissues and adjacent normal tissues in the GSE163416 data set. (B) The expression of *hsa_circ_0006646* in GC tissues and matched normal gastric mucosal epithelium tissues. ***P<0.001. (C) Kaplan-Meier analysis of the relationship between expression of *hsa_circ_0006646* and GC patients' overall survival. *hsa_circ_0006646* expression was negatively correlated with the OS of GC patients. (D) qRT-PCR analysis of *hsa_circ_0006646* in the GC cell lines. Data are the mean $\pm$ SD. ***P<0.001 compared with GES-1 cells. (E) The head-to-tail splicing of *hsa_circ_0006646* in the qRT-PCR product as detected with Sanger sequencing. (F) Combining PCR with an electrophoresis assay indicated the expression of *hsa_circ_0006646* in AGS and HGC27 cells. (G) qRT-PCR analysis of *hsa_circ_0006646* in GC cell lines after RNase R treatment. ***P<0.001 compared with MOCK. qRT-PCR, quantitative real-time polymerase chain reaction; GC, gastric cancer; OS, overall survival.

Table 3 Correlation between *hsa_circ_0006646* expression and clinicopathologic characteristics in GC patients

Characteristics	Case	<i>hsa_circ_0006646</i>		χ^2	P
		High (%)	Low (%)		
Age, years				0.326	0.724
<60	22	14 (63.6)	8 (36.4)		
≥60	13	7 (53.8)	6 (46.2)		
Gender				0.761	0.477
Male	23	15 (65.2)	8 (34.8)		
Female	12	6 (50.0)	6 (50.0)		
TNM stage				9.333	0.006**
I–II	10	2 (20.0)	8 (80.0)		
III–IV	25	19 (76.0)	6 (24.0)		
Lymph node invasion				7.619	0.010*
Negative (N0)	7	1 (14.3)	6 (85.7)		
Positive (N1–N3)	28	20 (71.4)	8 (28.6)		
Histological grade				1.414	0.283
Low	24	16 (66.7)	8 (33.3)		
Middle-High	11	5 (45.5)	6 (54.5)		

Data were analyzed by chi-squared test. *P<0.05; **P<0.01. GC, gastric cancer; TNM, tumor-node-metastasis.

on *hsa_circ_0006646* for further study. We analyzed the correlation between *hsa_circ_0006646* expression and clinical features. We found that *hsa_circ_0006646* expression was positively correlated with TNM stage and lymph node invasion (Table 3). Furthermore, overall survival (OS) curves was completed by using the Kaplan-Meier analysis. Patients who had high levels of *hsa_circ_0006646* had significantly lower overall survival rate (Figure 1C). Meanwhile, consistent with the results of GC specimens, the expression of *hsa_circ_0006646* was significantly higher in GC cell lines as compared to GES-1 cells (Figure 1D). To verify whether *hsa_circ_0006646* was present in GC in the form of circRNA, we investigated the structure of *hsa_circ_0006646* based on circBase database annotation. The results indicated that *hsa_circ_0006646* was located at chromosome 8q24.3 (NM_001199649) and derived from exon 3 and exon 4 of the *PTK2* gene with a length of 394 nt (Figure 1E). Sanger sequencing confirmed that the PCR products amplified using the divergent primers contained the head-to-tail splicing site of *hsa_circ_0006646*, and the sequence was consistent with that of the circBase database annotation (Figure 1E). To detect whether the head-to-tail splicing of

hsa_circ_0006646 results from trans-splicing or genomic rearrangements, we designed convergent primers and divergent primers, which were used to amplify *PTK2* mRNA and *hsa_circ_0006646*, respectively. The gel electrophoresis results showed that *hsa_circ_0006646* could be detected in cDNA but not gDNA, indicating that the loop structure of *hsa_circ_0006646* was derived from reverse splicing (Figure 1F). Considering that circRNAs are more stable than are linear RNAs (17), we further analyzed the stability of *hsa_circ_0006646* by conducting RNase R digestion assay. The results demonstrated that *hsa_circ_0006646* was resistant to RNase R treatment, while linear *PTK2* was significantly degraded after RNase R treatment, further confirming the circular form of *hsa_circ_0006646* (Figure 1G). Taken together, these results demonstrated that *hsa_circ_0006646* was an abundant, circular and stable transcript in GC.

***hsa_circ_0006646* knockdown suppressed the proliferation, migration, invasion, and EMT in GC cells in vitro**

To further elucidate the functional mechanism of *hsa_circ_0006646*

circ_0006646 in GC, we next investigated its effects on the malignant behaviors of GC cells. As AGS and HGC27 cell lines exhibited a relatively higher expression of *hsa_circ_0006646* as compared to the other GC cell lines (Figure 1D), we performed the following experiments using these two cell lines. si-*hsa_circ_0006646*#1 and si-*hsa_circ_0006646*#2 significantly reduced the expression of *hsa_circ_0006646* (Figure 2A). Then, we constructed sh-*hsa_circ_0006646*#1 and sh-*hsa_circ_0006646*#2 based on the sequences of si-*hsa_circ_0006646*#1 and si-*hsa_circ_0006646*#2 to further assess the effect of *hsa_circ_0006646* on the proliferation, migration, and invasion in GC cells. Through CCK-8 assay, we found that *hsa_circ_0006646* knockdown significantly suppressed the proliferation in AGS and HGC27 cells (Figure 2B). Additionally, we conducted a colony formation assay and found that the colony numbers were decreased by *hsa_circ_0006646* knockdown in AGS and HGC27 cells (Figure 2C). These experiments suggested that *hsa_circ_0006646* knockdown inhibited the proliferation of GC cells. Following this, wound healing and transwell assays were carried out to examine the effects of *hsa_circ_0006646* on the migration and invasion of GC cells. The results demonstrated that the migration and invasion were remarkably suppressed by *hsa_circ_0006646* knockdown in AGS and HGC27 cells (Figure 2D,2E). As EMT is a critical process facilitating the initiation and progression of GC, we then investigated whether EMT was involved in the tumor-promoting functions of *hsa_circ_0006646*. As Figure 2F shows, *hsa_circ_0006646* knockdown decreased the expression of N-cadherin, Vimentin, and Snail and increased the expression of E-cadherin in AGS and HGC27 cells. Taken together, these findings suggested that *hsa_circ_0006646* promoted the malignant behaviors and EMT in GC cells in vitro.

***hsa_circ_0006646* bound to miR-665 in GC cells**

Accumulating studies have shown that circRNAs mainly exhibited their functions in tumor progression by sponging to miRNAs and then regulating subsequent gene expression (18,19). Thus, the online bioinformatics algorithms circBank (<http://www.circbank.cn/>) and circInteractome (<https://circinteractome.nia.nih.gov/>) were adopted to predict potential miRNAs which might be sponged by *hsa_circ_0006646*. By overlapping the results from the above 2 algorithms, we found 3 miRNAs (*miR-*

139-3p, *miR-1322*, and *miR-665*) as the candidates showing potential to be sponged by *hsa_circ_0006646* (Figure 3A). Then, we detected their expressions in AGS and HGC27 cells after transfection of sh-*hsa_circ_0006646*#1 or sh-NC. The results showed that the expressions of *miR-139-3p*, *miR-1322*, and *miR-665* were significantly increased in the AGS and HGC27 cells transfected with sh-*hsa_circ_0006646*#1 compared with the cells transfected with sh-NC (Figure 3B). As multiple studies revealed that *miR-665* was a tumor-suppressive miRNA in GC, we selected *miR-665* as the downstream target of *hsa_circ_0006646* in subsequent study (20-22). Then, we explored the colocalization of *hsa_circ_0006646* and *miR-665* in GC cells by conducting FISH. The result demonstrated that *hsa_circ_0006646* and *miR-665* were mainly located in the cytoplasm of AGS and HGC27 cells (Figure 3C), suggesting that *hsa_circ_0006646* had potential to sponge *miR-665* in GC. To further study the correlation between *miR-665* and *hsa_circ_0006646*, we transfected *miR-665* inhibitor and *miR-665* mimic into AGS and HGC27 cells and then detected the expression of *hsa_circ_0006646* with qRT-PCR. As Figure 3D shows, *miR-665* inhibitor and *miR-665* mimic increased and decreased the expression of *hsa_circ_0006646*, respectively, in AGS and HGC27 cells. As there was a potential binding site on the transcript of *hsa_circ_0006646* to interact with *miR-665* (Figure 3E), we constructed *hsa_circ_0006646*-WT and *hsa_circ_0006646*-MUT plasmids to conduct a luciferase reporter assay. Then, we transfected *hsa_circ_0006646*-WT or *hsa_circ_0006646*-MUT plasmid into AGS and HGC27 cells and then co-transfected them with *miR-665* mimics. The results showed that transfection of *miR-665* mimics significantly reduced the luciferase activity in the GC cells transfected with *hsa_circ_0006646*-WT but did not reduce the luciferase activity of the GC cells transfected with *hsa_circ_0006646*-MUT, indicating that *hsa_circ_0006646* acted as a ceRNA to sponge *miR-665* specifically at the seed sequence (Figure 3F). Meanwhile, to determine whether *hsa_circ_0006646* and *miR-665* formed an RNA-induced silencing complex (RISC), an Ago2-RIP assay was conducted in AGS and HGC27 cells. As shown in Figure 3G, *hsa_circ_0006646* and *miR-665* were substantially enriched in Ago2-containing beads compared with those harboring control IgG, indicating that endogenous binding might occur between *hsa_circ_0006646* and *miR-665*. In summary, *hsa_circ_0006646* acted as a ceRNA to sponge *miR-665* in GC cells.





Figure 2 *hsa_circ_0006646* knockdown suppressed proliferation, migration and invasion in GC cells *in vitro*. (A) The efficacy of si-RNAs for knocking down *hsa_circ_0006646* in AGS and HGC27 cells. **P<0.01 and ***P<0.001 compared with si-NC. (B) The effect of *hsa_circ_0006646* knockdown on proliferation in AGS and HGC27 cells as detected with CCK-8 assay. ***P<0.001 compared with sh-NC. (C) The effect of *hsa_circ_0006646* knockdown on colony formation in AGS and HGC27 cells as detected with a colony formation experiment (magnification 200×, crystal violet staining). ***P<0.001 compared with sh-NC. (D) The effect of *hsa_circ_0006646* knockdown on invasion in AGS and HGC27 cells as detected with transwell assay (magnification ×200, crystal violet staining). ***P<0.001 compared with sh-NC. (E) The effect of *hsa_circ_0006646* knockdown on migration in AGS and HGC27 cells as detected with a wound healing assay (magnification ×200). **P<0.01 and ***P<0.001 compared with sh-NC. (F) The effect of *hsa_circ_0006646* knockdown on EMT-related proteins in AGS and HGC27 cells as detected with Western blotting. qRT-PCR, quantitative real-time polymerase chain reaction; si, small interfering; sh, short hairpin; NC, negative control; OD, optical density; CCK-8, Cell Counting Kit-8; EMT, epithelial-mesenchymal transition.






Figure 3 *hsa_circ_0006646* served as a molecule sponge for *miR-665* in GC. (A) Schematic illustration exhibiting the overlapping of the miRNAs that showed potential to be sponged by *hsa_circ_0006646* as predicted by analyzing circBank and circInteractome. (B) The changes in the expression of miRNAs after knocking down *hsa_circ_0006646* in AGS and HGC27 cells. * $P < 0.05$ and *** $P < 0.001$ compared with sh-NC. (C) FISH assay showed that *hsa_circ_0006646* and *miR-665* were predominantly localized in the cytoplasm. *hsa_circ_0006646* and *miR-665* were stained green and red, respectively. Nuclei were stained with DAPI (magnification 60 $\times$). (D) The effect of *miR-665* mimic and inhibitor on the expression of *hsa_circ_0006646*. *** $P < 0.001$ compared with miRNA mimic NC or miRNA inhibitor NC (E) The potential *miR-665* target sites in *hsa_circ_0006646* transcript. (F) The luciferase activities of the *hsa_circ_0006646* luciferase reporter vector (WT or MUT) measured after transfection with *miR-665* mimics or mimic NC into AGS and HGC27 cells. ** $P < 0.01$ and *** $P < 0.001$ compared with *hsa_circ_0006646*-MUT. (G) Ago2-RIP assay to detect the enrichment of *hsa_circ_0006646* and *miR-665* in Ago2-immunoprecipitates. *** $P < 0.001$ compared with IgG. Input was used as the internal control to normalize the expression of *hsa_circ_0006646* and *miR-665*. sh, short hairpin; NC, negative control; FISH, Fluorescence in situ hybridization; RIP, RNA immunoprecipitation; DAPI, 4',6-diamidino-2-phenylindole; WT, wild-type; MUT, mutated-type.

hsa_circ_0006646 upregulated *HMGB1* by sponging *miR-665* in GC

miRNAs interact with the 3'-UTR of target genes to regulate their expressions (23). Therefore, we predicted the downstream target of *miR-665* by analyzing the bioinformatics algorithms FunRich, miRWalk, TargetScan, and miRDB (12-15). By overlapping the results of analysis, we found 6 genes exhibiting possibly regulated by *miR-665*: *HMGB1*, limb and CNS expressed 1 like (*LIX1L*), calcium regulated heat stable protein 1 (*CARHSP1*), proteasome inhibitor subunit 1 (*PSMF1*), solute carrier family 37 member 3 (*SLC37A3*), and synaptotagmin 2 (*SYT2*) (Figure 4A). Among these genes, only *HMGB1* was reported to be involved in the progression of GC (24,25). Thus, we chose *HMGB1* as the target gene of *miR-665* in subsequent study. *HMGB1* mRNA contains the miRNA recognition elements (MRE) of *miR-665*, implying that *miR-665* might be the direct target of *HMGB1* (Figure 4B). Furthermore, luciferase reporter plasmids with the wild type *HMGB1* mRNA 3'-UTR-WT and *HMGB1* mRNA

3'-UTR-MUT in the binding sites of *miR-665* were constructed. The plasmids harboring *HMGB1* mRNA 3'-UTR-WT or *HMGB1* mRNA 3'-UTR-MUT were co-transfected into AGS and HGC27 cells with *miR-665* mimic. Luciferase reporter assays showed that the *miR-665* mimic significantly decreased the luciferase activity of AGS and HGC27 cells transfected with *HMGB1*-3'-UTR-WT, but not in those with *HMGB1*-3'-UTR-MUT (Figure 4C). To further validate whether *HMGB1* is regulated by *miR-665* in GC cells, we assayed the expression of *HMGB1* in GC cells after transfection of *miR-665* mimic via Western blotting. Transfection of *miR-665* mimic significantly decreased the expression of *HMGB1* in AGS and HGC27 cells (Figure 4D). To verify whether *hsa_circ_0006646* regulates the expression of *HMGB1* by sponging *miR-665*, we conducted a miRNA rescue experiment. As shown in Figure 4E, knockdown of *hsa_circ_0006646* decreased the expression of *HMGB1* in AGS and HGC27 cells while co-transfection of *miR-665* inhibitor rescued this suppression. Similarly, co-transfection of *miR-665* mimic downregulated




Figure 4 The *hsa_circ_0006646*-*miR-665*-*HMGB1* axis in GC. (A) Schematic illustration exhibiting the overlapping of the target genes of *miR-665* predicted by FunRich, miRWalk, TargetScan, and miRDB. (B) The sequences of *HMGB1* 3'-UTR-WT and *HMGB1* 3'-UTR-MUT used in luciferase reporter assay for validating the binding 3'-UTR of *HMGB1* mRNA and *miR-665*. (C) The luciferase activities of the *HMGB1* luciferase reporter vector (WT or MUT) measured after transfection with *miR-665* mimics or mimic NC into AGS and HGC27 cells. **P<0.01 and ***P<0.001 compared with *hsa_circ_0006646*-MUT. (D) The effect of *miR-665* mimic on the expression of *HMGB1* in AGS and HGC27 cells. (E) The *hsa_circ_0006646*-*miR-665*-*HMGB1* axis in AGS and HGC27 cells. (F) The correlation between *hsa_circ_0006646* and *miR-665* in GC specimens (n = 35). (G) The representative IHC staining of *HMGB1* in GC tissues (magnification 200×, DAB and hematoxylin). (H) The expressions of *hsa_circ_0006646* and *miR-665* in *HMGB1*-positive and *HMGB1*-negative GC specimens. *P<0.05, ***P<0.001. GC, gastric cancer; NC, negative control; WT, wild-type; MUT, mutated-type; IHC, Immunohistochemistry; DAB, 3,3'-diaminobenzidine.

the expression of *HMGB1* in the AGS and HGC27 cells that were transfected with sh-NC. Next, we evaluated the *hsa_circ_0006646*-*miR-665*-*HMGB1* axis in GC tissues. As anticipated, the expressions of *hsa_circ_0006646* and *miR-665* were negatively correlated ($r=-0.3805$; $P=0.02$; Figure 4F). Subsequently, we detected the expression of *HMGB1* in GC specimens through immunohistochemistry

(IHC). As shown in Figure 4G, the staining of *HMGB1* was present in the nucleus of cancer cells in GC tissues. In the validation cohort, 20 cases (57.14%) exhibited a positive expression of *HMGB1*. Moreover, the expression of *hsa_circ_0006646* was higher and the expression of *miR-665* was lower in the *HMGB1*-positive group as compared to the *HMGB1*-negative group (Figure 4H). Taken together,

these results provided evidence for the presence of a *hsa_circ_0006646-miR-665-HMGB1* axis in GC.

***hsa_circ_0006646-miR-665-HMGB1* axis promoted the proliferation, migration, invasion, and EMT in GC cells**

Numerous studies have revealed that *HMGB1* act as a tumor-promoter by activating the Wnt/ β -catenin signaling pathway (26,27); thus, we conducted miRNA rescue experiments to clarify the effect of *hsa_circ_0006646-miR-665-HMGB1* axis in GC. Western blotting assays demonstrated that knockdown of *hsa_circ_0006646* in AGS and HGC27 cells decreased the expression of β -catenin, Wnt3a, and c-Myc, the key elements of Wnt/ β -catenin signaling pathway, while co-transfection of *miR-665* inhibitor rescued this phenomenon (Figure 5A). Consequently, knockdown of *hsa_circ_0006646* decreased the expression of N-cadherin, Vimentin, and Snail and increased the expression of E-cadherin in AGS and HGC27 cells. Similarly, the above phenomenon was neutralized through co-transfection of *miR-665* inhibitor (Figure 5A). We then conducted CCK-8, colony formation, wound healing, and transwell assays to determine the effects of the *hsa_circ_0006646-miR-665-HMGB1* axis on the malignant biological behaviors of GC cells. The results demonstrated that the *hsa_circ_0006646-miR-665-HMGB1* axis promoted the proliferation, colony formation, migration, and invasion in AGS and HGC27 cells (Figure 5B-5F). In summary, these data demonstrated that the *hsa_circ_0006646-miR-665-HMGB1* axis promoted the progression of GC.


hsa_circ_0006646* enhanced the progression of GC *in vivo

To further explore the effects of *hsa_circ_0006646* on the progression of GC *in vivo*, a xenograft mouse model was established. The AGS cells transfected with sh-*hsa_circ_0006646*#1 or control group were subcutaneously injected into BALB/c nude mice. From the seventh day after injection, the tumor volumes were measured every 3 days to evaluate the growth of GC cells *in vivo*. After 28 days, the mice were killed, and the xenograft tumors were harvested and weighed. The results showed that knockdown of *hsa_circ_0006646* significantly retarded the tumor growth of AGS cells *in vivo* (Figure 6A,6B). As shown in Figure 6C, the tumor weights of the *hsa_circ_0006646* knockdown group were lighter than those of the control group. Then, we conducted Western blotting and IHC to confirm the effect of *hsa_circ_0006646* knockdown

on the expression of *HMGB1* *in vivo*. As anticipated, the expression of *HMGB1* was significantly downregulated in the *hsa_circ_0006646* knockdown group (Figure 6D,6E). Next, we performed Western blotting to evaluate the effect of *hsa_circ_0006646* knockdown on the expression of Wnt/ β -catenin pathway and EMT-related proteins *in vivo*. This revealed that in the *hsa_circ_0006646* knockdown group, the expressions of Wnt3a, β -catenin, c-Myc, N-cadherin, Vimentin, Snail were significantly decreased while the expression of E-cadherin was increased (Figure 6F). Furthermore, we detected the expression of β -catenin by performing IHC to verify the effect of the *hsa_circ_0006646-miR-665-HMGB1* axis *in vivo*. As shown in Figure 6G, the expression of β -catenin was significantly decreased in the *hsa_circ_0006646* knockdown group. Taken together, these findings demonstrated that *hsa_circ_0006646* promoted the progression of GC by upregulating *HMGB1* and activating the Wnt/ β -catenin signaling pathway *in vivo*.

Discussion

circRNAs are a new series of highly stable and abundant endogenous noncoding RNA (3). CircRNAs are pervasive but heterogeneous among multiple tissues and cell lines, the generation of circRNAs is regulated by non-canonical splicing or back-splicing events (17). Previous several pieces of studies considered circRNAs as transcriptional noise and aberrant splicing by-products (28-30). However, due to the development of high-throughput sequencing and bioinformatics analysis, an increasing number of circRNAs have given rise to a new perspective on understanding the key regulators in the development and progression of cancers (31-33). Numerous circRNAs have been proven to be aberrantly upregulated in GC, and it is relatively difficult for RNase R to degrade circRNAs as they exhibit greater stability than linear RNAs in body fluids. Therefore, circRNAs show high potential value in clinical diagnosis and evaluation of prognosis (34). For instance, circRNA *circSLIT2* is a novel diagnostic and prognostic biomarker for gastric cancer (35). In addition, *circRNA-ABCB10* promotes gastric cancer progression by sponging *miR-1915-3p* to upregulate *RaC1* (36). Moreover, *circFCHO2* promotes gastric cancer progression by activating the *JAK1/STAT3* pathway via sponging *miR-194-5p* (37). However, only some functions of circRNAs have been clarified in GC, limiting further study on improving those treatment strategies targeting key circRNAs. Therefore, it is necessary to elucidate the functions and clinical significance of novel






Figure 5 The *hsa_circ_0006646*-*miR-665*-*HMGB1* axis promotes proliferation, migration, invasion, and EMT in GC cells *in vitro*. (A) The effect of the *hsa_circ_0006646*-*miR-665*-*HMGB1* axis on the Wnt/ β -catenin pathway and EMT-related proteins. (B) The effect of the *hsa_circ_0006646*-*miR-665*-*HMGB1* axis on proliferation in AGS and HGC27 cells as detected with CCK-8 assay. (C) The effect of *hsa_circ_0006646*-*miR-665*-*HMGB1* axis on colony formation in AGS and HGC27 cells as detected with colony formation assay (magnification 200 $\times$, crystal violet staining). (D) The effect of the *hsa_circ_0006646*-*miR-665*-*HMGB1* axis on invasion in AGS and HGC27 cells as detected with Transwell assay (magnification 200 $\times$, crystal violet staining). (E,F) The effect of the *hsa_circ_0006646*-*miR-665*-*HMGB1* axis on migration in AGS and HGC27 cells as detected with wound healing assay (magnification 200 $\times$). *** $P < 0.001$. GC, gastric cancer; sh, short hairpin; NC, negative control; EMT, epithelial-mesenchymal transition; OD, optical density; CCK-8, Cell Counting Kit-8.

circRNAs involved in the progression of GC.

In this study, by analyzing the public GEO database and bioinformatics algorithms, we first identified *hsa_circ_0006646* as a critical circRNA upregulated in GC. *hsa_circ_0006646* was found to originate from exon 3 and exon 4 of its parent gene, *PTK2*. The roles of different circRNAs originating from the *PTK2* gene in cancers have already been examined. For instance, *hsa_circ_0005273*, which originates from exons 27, 28, and 29 of *PTK2*, promotes growth and metastasis of colorectal cancer (38). Moreover, *circPTK2* was found to modulate migration and invasion via *miR-136/NFIB* signaling in triple-negative breast cancer cells *in vitro* (39). Regarding GC, *circPTK2* suppresses the progression of GC by targeting the *miR-196a-3p-AATK* axis (40). Besides, *circPTK2* inhibits the tumorigenesis and metastasis of GC by sponging *miR-134-5p* and activating *CELF2/PTEN* signaling (41). To our knowledge, the expression and function of *hsa_circ_0006646* in GC have not been elucidated. By analyzing the GC tissues and matched normal gastric mucosal epithelium tissues, we found that *hsa_circ_0006646* was significantly upregulated in GC tissues and its high expression was correlated with TNM stage, lymph node metastasis and poor prognosis of patients with GC, indicating that *hsa_circ_0006646* might be a potential tumor-promoting circRNA. To reveal the biological functions of *hsa_circ_0006646*, we knocked

down *hsa_circ_0006646* expression and then evaluated its effects on the malignant behaviors in GC cells. *hsa_circ_0006646* knockdown significantly inhibited the proliferation, colony formation, migration, and invasion in GC cells. Furthermore, *hsa_circ_0006646* knockdown increased the expression of E-cadherin and decreased the expression of N-cadherin, Vimentin, and Snail in GC cells. Taken together, our results suggest that *hsa_circ_0006646* functions as a tumor-promoting circRNA by facilitating the proliferation, colony formation, migration, invasion, and EMT in GC cells.

It has been reported that exon-intron and intron-derived circRNAs mainly function in the cell nucleus by promoting the transcription of their parent gene. In contrast, exon-derived circRNAs do not affect the expression of their parent genes due to their cytoplasmic location (42). The most well-studied functional mechanisms of cytoplasmic circRNAs include their acting as ceRNAs to sponge miRNAs and thereby regulate the expression of target genes (43). Therefore, we applied the bioinformatics algorithms circBank and circInteractome to predict the miRNAs that were potentially sponged by *hsa_circ_0006646*. By overlapping the analyses, we screened out 3 candidate miRNAs exhibiting potential to be the downstream miRNAs of *hsa_circ_0006646* in GC. Among these 3 miRNAs, *miR-665* exhibited the most significant upregulation in GC cells




Figure 6 *bsa_circ_0006646* promoted tumorigenesis and progression of GC *in vivo*. (A) The xenograft tumors derived from AGS cells transfected with sh-*bsa_circ_0006646*#1 or sh-NC. (B) The growth of GC xenograft tumor volumes. (C) The weights of GC xenograft tumor. (D) The expression of *HMGB1* in xenograft tumors as detected with Western blotting. (E) Representative IHC staining of *HMGB1* in xenograft tumors (magnification 200×, DAB and hematoxylin). (F) The expression of Wnt/ β -catenin pathway and EMT-related proteins in xenograft tumors. (G) Representative IHC staining of β -catenin in xenograft tumors (magnification 200×, DAB and hematoxylin). *** $P < 0.001$. sh, short hairpin; NC, negative control; GC, gastric cancer; EMT, epithelial-mesenchymal transition; IHC, Immunohistochemistry; DAB, 3,3'-diaminobenzidine.

after *bsa_circ_0006646* knockdown. Next, we conducted a FISH assay and discovered that *bsa_circ_0006646* and *miR-665* were co-located in the cytoplasm of GC cells. Furthermore, we performed dual-luciferase reporter and RIP assay and found that *bsa_circ_0006646* directly bound with *miR-665* to form a RISC. Then, we employed the bioinformatics algorithms FunRich, miRWalk, TargetScan, and miRDB to determine the downstream target of *miR-665*. By overlapping the results, we found 6 genes exhibiting the potential to be regulated by *miR-665*, among which *HMGB1* was particularly noteworthy due to its concrete function in GC (24,44). *HMGB1* is a protein in the high mobility group box superfamily (45). As a chromatin component common in mammalian cells, *HMGB1* plays a role in the pathogenesis of inflammation, trauma, immune system diseases, and malignant tumors (46). Accumulating

studies have demonstrated that *HMGB1* is expressed at high level in multiple malignant tumors (47-49). *HMGB1* is a key regulator in EMT, promoting the invasion, metastasis, and drug resistance in cancers by regulating various signaling pathways (50,51). For instance, *HMGB1* activates the Wnt/ β -catenin and *RAGE/NF- κ B* signaling pathways to promote the EMT process of lung cancer cells (26) and prostate cancer cells, (52) respectively. Additionally, *HMGB1* promotes snail-mediated EMT in glioblastoma cells via promoting the degradation of GSK-3 β (53). High expression of *HMGB1* has also been proven to be an indicator of poor prognosis in GC patients (54). In this study, miRNA rescue experiments confirmed there to be a *bsa_circ_0006646*-*miR-665*-*HMGB1* axis in GC cells, with this axis upregulating E-cadherin and downregulating N-cadherin, Vimentin, and Snail. The downregulation of E-cadherin

and upregulation of N-cadherin, Vimentin, and Snail are considered to be the fundamental processes of EMT (55). Thus, these results indicated that *hsa_circ_0006646* promotes EMT in GC cells by regulating the *miR-665-HMGB1* axis. As it concerns the functional mechanisms, the *hsa_circ_0006646-miR-665-HMGB1* axis increased the expression of crucial elements involved in Wnt/ β -catenin pathways, including β -catenin, Wnt3a, and c-Myc. As a result, knocking down *hsa_circ_0006646* suppressed the proliferation, colony formation, invasion, and migration in GC cells, and *miR-665* inhibitor partially abolished this suppression. Furthermore, we confirmed the existence of a *hsa_circ_0006646-miR-665-HMGB1* axis in GC specimens. Therefore, the identification of the *hsa_circ_0006646-miR-665-HMGB1* axis expands our knowledge of the regulatory mechanism underlying GC pathogenesis and progression.

Conclusions

To our knowledge, this is the first study to thoroughly investigate the expression, regulation, and function of *hsa_circ_0006646* in GC. Our findings provide evidence for the existence and biological functions of the *hsa_circ_0006646-miR-665-HMGB1* axis in GC, which promoted the proliferation, colony formation, migration, and invasion in GC by regulating Wnt/ β -catenin signaling. These findings lay the foundation for further clinical study on *hsa_circ_0006646-miR-665-HMGB1* axis and provide a novel insight into the mechanism underlying circRNA-induced progression of GC.

Acknowledgments

We would like to thank Prof. Huixian Cui from the International Cooperation Laboratory of Stem Cell Research, Hebei Medical University, for his kind help, as well as those patients enrolled in this study.

Funding: This work was sponsored by the National Natural Science Foundation of China (grant Nos. 81871894 and 91942314) and the Natural Science Foundation of Hebei Province (grant No. H2021206070).

Footnote

Reporting Checklist: The authors have completed the ARRIVE reporting checklist. Available at <https://jgo.amegroups.com/article/view/10.21037/jgo-23-240/rc>

Data Sharing Statement: Available at <https://jgo.amegroups.com/article/view/10.21037/jgo-23-240/dss>

Peer Review File: Available at <https://jgo.amegroups.com/article/view/10.21037/jgo-23-240/prf>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://jgo.amegroups.com/article/view/10.21037/jgo-23-240/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study was approved by the Ethics Committee of Fourth Hospital of Hebei Medical University (No. 2019-082), and eligible patients signed informed consent. This study was conducted in accordance with the principles of the Declaration of Helsinki (as revised in 2013). All animal experiments were performed under a project license granted by the Ethics Committee of Fourth Hospital of Hebei Medical University (No. 2020-056) and in compliance with the Fourth Hospital of Hebei Medical University guidelines for the care and use of animals.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. *CA Cancer J Clin* 2021;71:7-33.
2. Ilic M, Ilic I. Epidemiology of stomach cancer. *World J Gastroenterol* 2022;28:1187-203.
3. Chen L, Shan G. CircRNA in cancer: Fundamental mechanism and clinical potential. *Cancer Lett* 2021;505:49-57.
4. Norwood DA, Montalvan EE, Dominguez RL, et al. Gastric Cancer: Emerging Trends in Prevention,

- Diagnosis, and Treatment. *Gastroenterol Clin North Am* 2022;51:501-18.
5. Cheng X, Ai K, Yi L, et al. The mmu_circRNA_37492/hsa_circ_0012138 function as potential ceRNA to attenuate obstructive renal fibrosis. *Cell Death Dis* 2022;13:207.
 6. Chan JJ, Tay Y. Noncoding RNA:RNA Regulatory Networks in Cancer. *Int J Mol Sci* 2018;19.
 7. Zhang M, Bai X, Zeng X, et al. circRNA-miRNA-mRNA in breast cancer. *Clin Chim Acta* 2021;523:120-30.
 8. Chen LL. The expanding regulatory mechanisms and cellular functions of circular RNAs. *Nat Rev Mol Cell Biol* 2020;21:475-90.
 9. Gong G, She J, Fu D, et al. CircUBR5 acts as a ceRNA for miR-1179 to up-regulate UBR5 and to promote malignancy of triple-negative breast cancer. *Am J Cancer Res* 2022;12:2539-57.
 10. Pei S, Ma C, Chen J, et al. CircFOXO1 acts as a ceRNA to upregulate SMAD2 and promote the progression of nasopharyngeal carcinoma. *Mol Genet Genomic Med* 2022;10:e1914.
 11. Liu N, Jiang F, Chen Z, et al. circIFT80 Functions as a ceRNA for miR-142, miR-568, and miR-634 and Promotes the Progression of Colorectal Cancer by Targeting β -Catenin. *Dis Markers* 2022;2022:8081246.
 12. Fonseka P, Pathan M, Chitti SV, et al. FunRich enables enrichment analysis of OMICS datasets. *J Mol Biol* 2021;433:166747.
 13. Sticht C, De La Torre C, Parveen A, et al. miRWalk: An online resource for prediction of microRNA binding sites. *PLoS One* 2018;13:e0206239.
 14. Agarwal V, Bell GW, Nam JW, et al. Predicting effective microRNA target sites in mammalian mRNAs. *Elife* 2015;4.
 15. Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA targets. *Nucleic Acids Res* 2020;48:D127-d31.
 16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001;25:402-8.
 17. Kristensen LS, Andersen MS, Stagsted LVW, et al. The biogenesis, biology and characterization of circular RNAs. *Nat Rev Genet* 2019;20:675-91.
 18. Zhang W, Liu H, Jiang J, et al. CircRNA circFOXK2 facilitates oncogenesis in breast cancer via IGF2BP3/miR-370 axis. *Aging (Albany NY)* 2021;13:18978-92.
 19. Hashemi N, Jamshidian A, Babaei S, et al. Reconstruction and analysis of circRNA-miRNA-mRNA network in the pathology of lung cancer. *Klin Onkol* 2022;35:461-72.
 20. Zhang M, Wang S, Yi A, et al. microRNA-665 is down-regulated in gastric cancer and inhibits proliferation, invasion, and EMT by targeting PPP2R2A. *Cell Biochem Funct* 2020;38:409-18.
 21. Fang X, Bai Y, Zhang L, et al. MicroRNA-665 regulates the proliferation, apoptosis and adhesion of gastric cancer cells by binding to cadherin 3. *Oncol Lett* 2021;21:494.
 22. He C, Liu Y, Li J, et al. LncRNA RPSAP52 promotes cell proliferation and inhibits cell apoptosis via modulating miR-665/STAT3 in gastric cancer. *Bioengineered* 2022;13:8699-711.
 23. Toden S, Zumwalt TJ, Goel A. Non-coding RNAs and potential therapeutic targeting in cancer. *Biochim Biophys Acta Rev Cancer* 2021;1875:188491.
 24. Tang T, Wang S, Cai T, et al. High mobility group box 1 regulates gastric cancer cell proliferation and migration via RAGE-mTOR/ERK feedback loop. *J Cancer* 2021;12:518-29.
 25. Takaki W, Konishi H, Matsubara D, et al. Role of Extracellular High-Mobility Group Box-1 as a Therapeutic Target of Gastric Cancer. *Int J Mol Sci* 2022;23.
 26. Wang XH, Zhang SY, Shi M, et al. HMGB1 Promotes the Proliferation and Metastasis of Lung Cancer by Activating the Wnt/ β -Catenin Pathway. *Technol Cancer Res Treat* 2020;19:1533033820948054.
 27. Wang S, Du S, Lv Y, et al. MicroRNA-665 inhibits the oncogenicity of retinoblastoma by directly targeting high-mobility group box 1 and inactivating the Wnt/ β -catenin pathway. *Cancer Manag Res* 2019;11:3111-23.
 28. Lee ECS, Elhassan SAM, Lim GPL, et al. The roles of circular RNAs in human development and diseases. *Biomed Pharmacother* 2019;111:198-208.
 29. Santer L, Bär C, Thum T. Circular RNAs: A Novel Class of Functional RNA Molecules with a Therapeutic Perspective. *Mol Ther* 2019;27:1350-63.
 30. Nisar S, Bhat AA, Singh M, et al. Insights Into the Role of CircRNAs: Biogenesis, Characterization, Functional, and Clinical Impact in Human Malignancies. *Front Cell Dev Biol* 2021;9:617281.
 31. Zhang W, Liu T, Li T, et al. Hsa_circRNA_102002 facilitates metastasis of papillary thyroid cancer through regulating miR-488-3p/HAS2 axis. *Cancer Gene Ther* 2021;28:279-93.
 32. Zheng L, Liang H, Zhang Q, et al. circPTEN1, a circular RNA generated from PTEN, suppresses cancer progression through inhibition of TGF- β /Smad signaling. *Mol Cancer* 2022;21:41.

33. Xi Y, Shen Y, Wu D, et al. CircBCAR3 accelerates esophageal cancer tumorigenesis and metastasis via sponging miR-27a-3p. *Mol Cancer* 2022;21:145.
34. Ghafouri-Fard S, Honarmand Tamizkar K, Jamali E, et al. Contribution of circRNAs in gastric cancer. *Pathol Res Pract* 2021;227:153640.
35. Wang L, Xiao S, Zheng Y, et al. CircRNA circSLIT2 is a novel diagnostic and prognostic biomarker for gastric cancer. *Wien Klin Wochenschr* 2023.
36. Liu J, Qiu G, Wang H, et al. CircRNA-ABCB10 promotes gastric cancer progression by sponging miR-1915-3p to upregulate RaC1. *Dig Liver Dis* 2022;54:896-904.
37. Zhang Z, Sun C, Zheng Y, et al. circFCHO2 promotes gastric cancer progression by activating the JAK1/STAT3 pathway via sponging miR-194-5p. *Cell Cycle* 2022;21:2145-64.
38. Yang H, Li X, Meng Q, et al. CircPTK2 (*hsa_circ_0005273*) as a novel therapeutic target for metastatic colorectal cancer. *Mol Cancer* 2020;19:13.
39. Wang M, Chen D, Zhang H, et al. Circular RNA circPTK2 modulates migration and invasion via miR-136/NFIB signaling on triple-negative breast cancer cells in vitro. *Inflamm Res* 2022;71:409-21.
40. Gao L, Xia T, Qin M, et al. CircPTK2 Suppresses the Progression of Gastric Cancer by Targeting the MiR-196a-3p/AATK Axis. *Front Oncol* 2021;11:706415.
41. Fan HN, Zhao XY, Liang R, et al. CircPTK2 inhibits the tumorigenesis and metastasis of gastric cancer by sponging miR-134-5p and activating CELF2/PTEN signaling. *Pathol Res Pract* 2021;227:153615.
42. Cortés-López M, Miura P. Emerging Functions of Circular RNAs. *Yale J Biol Med* 2016;89:527-37.
43. Goodall GJ, Wickramasinghe VO. RNA in cancer. *Nat Rev Cancer* 2021;21:22-36.
44. Chung HW, Lim JB. High-mobility group box-1 contributes tumor angiogenesis under interleukin-8 mediation during gastric cancer progression. *Cancer Sci* 2017;108:1594-601.
45. Ye M, Hou H, Shen M, et al. Circular RNA circFOXMI1 Plays a Role in Papillary Thyroid Carcinoma by Sponging miR-1179 and Regulating HMGB1 Expression. *Mol Ther Nucleic Acids* 2020;19:741-50.
46. Xue J, Suarez JS, Minaai M, et al. HMGB1 as a therapeutic target in disease. *J Cell Physiol* 2021;236:3406-19.
47. Wang S, Zhang Y. HMGB1 in inflammation and cancer. *J Hematol Oncol* 2020;13:116.
48. Handke NA, Rupp ABA, Trimpop N, et al. Soluble High Mobility Group Box 1 (HMGB1) Is a Promising Biomarker for Prediction of Therapy Response and Prognosis in Advanced Lung Cancer Patients. *Diagnostics (Basel)* 2021;11.
49. Lv DJ, Song XL, Huang B, et al. HMGB1 Promotes Prostate Cancer Development and Metastasis by Interacting with Brahma-Related Gene 1 and Activating the Akt Signaling Pathway. *Theranostics* 2019;9:5166-82.
50. Luan X, Ma C, Wang P, et al. HMGB1 is negatively correlated with the development of endometrial carcinoma and prevents cancer cell invasion and metastasis by inhibiting the process of epithelial-to-mesenchymal transition. *Onco Targets Ther* 2017;10:1389-402.
51. Lei X, Hu X, Zhang T, et al. HMGB1 release promotes paclitaxel resistance in castration-resistant prostate cancer cells via activating c-Myc expression. *Cell Signal* 2020;72:109631.
52. Zhang J, Shao S, Han D, et al. High mobility group box 1 promotes the epithelial-to-mesenchymal transition in prostate cancer PC3 cells via the RAGE/NF-κB signaling pathway. *Int J Oncol* 2018;53:659-71.
53. Li H, Li J, Zhang G, et al. HMGB1-Induced p62 Overexpression Promotes Snail-Mediated Epithelial-Mesenchymal Transition in Glioblastoma Cells via the Degradation of GSK-3β. *Theranostics* 2019;9:1909-22.
54. Wu Z, Huang Y, Yuan W, et al. Expression, tumor immune infiltration, and prognostic impact of HMGs in gastric cancer. *Front Oncol* 2022;12:1056917.
55. Lambert AW, Weinberg RA. Linking EMT programmes to normal and neoplastic epithelial stem cells. *Nat Rev Cancer* 2021;21:325-38.

(English Language Editor: J. Gray)

Cite this article as: Qin J, Zhen S, Wang J, Lv W, Zhao Y, Duan Y, Liu T, Feng L, Wang G, Liu L. Function of *hsa_circ_0006646* as a competing endogenous RNA to promote progression in gastric cancer by regulating the *miR-665-HMGB1* axis. *J Gastrointest Oncol* 2023;14(3):1259-1278. doi: 10.21037/jgo-23-240